Benchmark upgraded NeoGenomics to Buy from Hold with a $20 price target. The company reported "solid" Q4 results and its reorganization plans looks doable, the analyst tells investors in a research note. The Q4 upside was driven by sales of the RaDaR MRD test through the Pharmaceutical Services business, which bodes well for 2023, contends the firm. It says the new management team is implementing a "credible" performance improvement program that is expected to bring the company to adjusted EBITDA profitability by Q4 of 2023.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NEO:
- Here’s Why NeoGenomics’ (NASDAQ:NEO) Q4 Results Thrilled Investors
- NeoGenomics sees 2023 revenue $545M-$555M, consensus $545.08M
- NeoGenomics reports Q4 adjusted EPS (6c), consensus (16c)
- NeoGenomics announces results from study of RaDaR assay
- Needham upgrades NeoGenomics to Buy amid revenue and margin growth
